GT200600008A - Direct compression formulation and process - Google Patents

Direct compression formulation and process

Info

Publication number
GT200600008A
GT200600008A GT200600008A GT200600008A GT200600008A GT 200600008 A GT200600008 A GT 200600008A GT 200600008 A GT200600008 A GT 200600008A GT 200600008 A GT200600008 A GT 200600008A GT 200600008 A GT200600008 A GT 200600008A
Authority
GT
Guatemala
Prior art keywords
process
direct compression
compression formulation
formulation
disintegration
Prior art date
Application number
GT200600008A
Other languages
Spanish (es)
Inventor
Sabine Pfeffer
Frank Schaefer
Ricardo Schneeberger
Paul Allen Sutton
Martin Friedrich Trueby
Wolfgang Wirth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US64464505P priority Critical
Priority to US69048405P priority
Application filed filed Critical
Publication of GT200600008A publication Critical patent/GT200600008A/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICION FARMACEUTICA DE INHIBIDOR DE DIPEPTIDILPEPTIDASA IV, PREFERENTEMENTE VILDAGLIPTINA EN FORMAS DE DOSIFICACION SOLIDAS, TALES COMO TABLETAS Y CAPSULAS QUE TIENEN LAS CARACTERISTICAS DESEADAS DE DUREZA, CAPACIDAD DE DESINTEGRACION Y DISOLUCION ACEPTABLE. The present invention REFERS TO PHARMACEUTICAL COMPOSITION OF DPPIV inhibitor, preferably vildagliptin in solid dosage forms, such as tablets and capsules having the desired characteristics of hardness, disintegration and dissolution OK.
GT200600008A 2005-01-18 2006-01-10 Direct compression formulation and process GT200600008A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US64464505P true 2005-01-18 2005-01-18
US69048405P true 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
GT200600008A true GT200600008A (en) 2006-08-09

Family

ID=36581880

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600008A GT200600008A (en) 2005-01-18 2006-01-10 Direct compression formulation and process

Country Status (19)

Country Link
US (3) US20060210627A1 (en)
EP (1) EP1841413A2 (en)
JP (1) JP2008527004A (en)
KR (1) KR20070100291A (en)
AR (1) AR052878A1 (en)
AU (2) AU2006206670B2 (en)
BR (1) BRPI0606731A2 (en)
CA (1) CA2593359A1 (en)
GT (1) GT200600008A (en)
IL (1) IL183762D0 (en)
MA (1) MA29171B1 (en)
MX (1) MX2007008679A (en)
NO (1) NO20074048L (en)
NZ (1) NZ555576A (en)
PE (1) PE10172006A1 (en)
RU (1) RU2007131503A (en)
TN (1) TNSN07274A1 (en)
TW (1) TW200637616A (en)
WO (1) WO2006078593A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ES2375625T3 (en) 2004-02-05 2012-03-02 Kyorin Pharmaceutical Co., Ltd. Bicyclo ester derivatives.
AU2005328701B2 (en) * 2004-06-17 2009-08-13 Merz Pharma Gmbh & Co. Kgaa Drinkable immediate release tablet made with direct compression of memantine or neramexane
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg A process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
JOP20180109A1 (en) * 2005-09-29 2019-01-30 Novartis Ag New Formulation
AU2006306420A1 (en) * 2005-10-25 2007-05-03 Merck Sharp & Dohme Corp. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
CA2633167A1 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
AU2007224066B2 (en) 2006-03-08 2011-10-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
CA2651089C (en) 2006-05-04 2018-02-20 Peter Sieger A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
PE02352011A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int pharmaceutical combinations comprising metformin and linagliptin
AU2008210988B2 (en) * 2007-02-01 2012-09-06 Allocure, Inc. Potentiation of stem cell homing and treatment of organ dysfunction or organ failure
WO2008114857A1 (en) * 2007-03-22 2008-09-25 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative
PE09382009A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int pharmaceutical composition comprising a benzene derivative substituted glucopyranosyl
DE102007040952A1 (en) * 2007-08-30 2009-03-05 Miele & Cie. Kg Upright vacuum cleaner
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int pharmaceutical composition comprising an inhibitor of dipeptidyl peptidase-4 (DPP4) and a companion drug
CN102026641A (en) * 2008-05-14 2011-04-20 株式会社三和化学研究所 Pharmaceutical preparation comprising DPP-IV inhibitor and other diabetes therapeutic agent in concomitant or combined form
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "Treatment for diabetes in patients unsuitable for therapy with metformin"
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
EP2322499A4 (en) 2008-08-07 2011-12-21 Kyorin Seiyaku Kk Process for production of bicycloý2.2.2¨octylamine derivative
WO2010018866A1 (en) * 2008-08-14 2010-02-18 杏林製薬株式会社 Stabilized pharmaceutical composition
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (en) 2009-01-29 2011-03-16 Boehringer Ingelheim Int DPP4 inhibitors and pharmaceutical compositions comprising them, useful for treating metabolic diseases in pediatric patients, particularly type 2 diabetes mellitus
PE02502012A1 (en) * 2009-02-13 2012-03-28 Boehringer Ingelheim Int pharmaceutical composition comprising diphenylmethane derivatives glucopyranosyl, pharmaceutical form thereof, process for their preparation
NZ594487A (en) 2009-02-13 2013-11-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
UY32427A (en) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh pharmaceutical composition, pharmaceutical form, process for their preparation, methods of treatment and uses thereof
BRPI1013639A2 (en) 2009-02-13 2016-04-19 Boehringer Ingelheim Int antidiabetic drugs
CN102438617A (en) 2009-03-27 2012-05-02 杏林制药株式会社 Matrix-type sustained release preparation containing basic additive
BR112012007092A2 (en) * 2009-09-30 2016-08-23 Boehringer Ingelheim Int Method for preparing a crystalline form of 1-chloro-4- (beta-D-glicopiranos-1-yl) -2- (4 - ((S) -tetraidrofuran-3-yloxy) benzyl) benzene
CN102574829B (en) 2009-09-30 2015-07-01 贝林格尔.英格海姆国际有限公司 Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US20110236477A1 (en) * 2009-10-02 2011-09-29 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
KR20170136017A (en) 2009-11-27 2017-12-08 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
EA201201508A1 (en) 2010-05-05 2013-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Combined therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201101809A1 (en) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi Ve Ticaret Anonim Şirketi Vildagliptin and glimepiride combination.
TR201010683A1 (en) 2010-12-21 2012-07-23 Sanovel İlaç San. Ve Tic. A.Ş. Vildagliptin formulations.
TR201107482A1 (en) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Tic.A.Ş. It bilayer combination of vildagliptin and gliclazide composition.
WO2013036213A1 (en) 2011-09-07 2013-03-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dpp-iv inhibitor formulations
EP2572704A1 (en) 2011-09-22 2013-03-27 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-Disintegrating Formulations of Vildagliptin
EP2578208B1 (en) 2011-10-06 2014-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2013179300A2 (en) 2012-05-04 2013-12-05 Megafine Pharma (P) Ltd. A process for the preparation of vildagliptin and its intermediate thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
AR092843A1 (en) 2012-06-05 2015-05-06 Takeda Pharmaceuticals Co solid preparation
WO2014013505A2 (en) * 2012-07-20 2014-01-23 Hetero Research Foundation Amorphous vildagliptin
EP2769712A1 (en) * 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3110449A1 (en) 2014-02-28 2017-01-04 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US20170014380A1 (en) 2014-03-06 2017-01-19 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Vildagliptin Formulation Process Under Inert Gas Atmosphere
TR201402685A1 (en) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical formulations of vildagliptin
US10342247B2 (en) 2014-07-21 2019-07-09 Roquette Freres Sugar compositions for tableting by direct compression
CN104817482B (en) * 2015-03-17 2017-05-10 宁波百思佳医药科技有限公司 2-substituted pyrrolidine compounds, preparation and use in the preparation of vildagliptin
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
EP3512505A1 (en) 2016-09-16 2019-07-24 Galenicum Health S.L. Vildagliptin pharmaceutical compositions
GR1009406B (en) * 2017-10-03 2018-11-26 Φαρματεν Αβεε Pharmaceutical composition comprising vildagliptin and method of preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
CO5150173A1 (en) * 1998-12-10 2002-04-29 Novartis Ag Compounds n- (substituted glycyl) -2-cyanopyrrolidines inhibitors of dipeptidyl peptidase-IV (DPP-IV) which are effective in treating conditions mediated by DPP-IV
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
WO2003080056A2 (en) * 2002-03-21 2003-10-02 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
WO2004024184A1 (en) * 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited Sustained release preparation
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (en) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma New imidazo-pyridinones substituted, their preparation and their use as medicacmentos
CA2519208A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
PE00212005A1 (en) 2003-04-16 2005-03-15 Novartis Ag Process for the preparation of 2-n-substituted cyanopyrrolidine
ES2332920T3 (en) * 2004-01-20 2010-02-15 Novartis Ag Process and direct compression formulation.
AU2005215136A1 (en) * 2004-02-20 2005-09-01 Novartis Ag DPP-IV inhibitors for treating neurodegeneration and cognitive disorders

Also Published As

Publication number Publication date
MX2007008679A (en) 2007-07-25
US20080299190A1 (en) 2008-12-04
RU2007131503A (en) 2009-05-10
MA29171B1 (en) 2008-01-02
JP2008527004A (en) 2008-07-24
AU2006206670B2 (en) 2010-04-15
AR052878A1 (en) 2007-04-11
AU2006206670A1 (en) 2006-07-27
TNSN07274A1 (en) 2008-12-31
IL183762D0 (en) 2008-04-13
CA2593359A1 (en) 2006-07-27
WO2006078593A2 (en) 2006-07-27
PE10172006A1 (en) 2006-10-31
US20060210627A1 (en) 2006-09-21
US20120015029A1 (en) 2012-01-19
AU2010201312A1 (en) 2010-04-22
WO2006078593A3 (en) 2006-09-14
NO20074048L (en) 2007-10-11
NZ555576A (en) 2010-12-24
KR20070100291A (en) 2007-10-10
BRPI0606731A2 (en) 2009-07-14
TW200637616A (en) 2006-11-01
EP1841413A2 (en) 2007-10-10

Similar Documents

Publication Publication Date Title
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
UA106634C2 (en) Solid pharmaceutical dosage form
CY1111967T1 (en) DOSAGE FORM containing oxycodone and naloxone
NO20064347L (en) Substituted 1,2,3,4-tetrahydroisokinolinderivater
CL2007001972A1 (en) Acid isopropyl ester 4- [6- (6-methanesulfonyl-2-methylpyridin-3-ylamino) -5-methyl-pyrimidin-4-yloxy] -piperidine-1-carboxylic acid, modulators of metabolism; pharmaceutical composition; and their use to treat metabolic disorders.
PE10172006A1 (en) pharmaceutical formulation by direct compression of an inhibitor of dipeptidyl peptidase IV and process
UA115131C2 (en) Compounds boronatnoho ether and its pharmaceutical formulations
BRPI1009324A2 (en) Compounds and / or pharmaceutically acceptable thereof, pharmaceutical composition and their uses
CR11267A (en) solid preparation containing metformin hydrochloride and alogliptin
CL2011001966A1 (en) pharmaceutical composition comprising diphenylmethane derivatives as inhibitor glucopyranosyl SGLT-2; dosage form comprising a pharmaceutical composition; Method of preparation and use in glycemic control.
UY31272A1 (en) Acid azabifenilaminobenzoico novel
CR9580A (en) Inhibitors of Akt activity
CL2007001166A1 (en) pyrimidine derivatives condensed compounds, inhibitors of PI3K; processes for preparing the compounds; pharmaceutical composition that comprises; use of the compounds in the preparation of medicines; process for preparing the pharmaceutical composition; and kit that includes the pharmaceutical composition
RS52922B (en) Compositions and uses for treating multiple sclerosis
GT201200250A (en) Ariltriazolonas linked to bisaryl and use
AR109796A2 (en) Pharmaceutical dosage forms
RU2008116316A (en) The new composition
UA89220C2 (en) Method for treatment of hiv/aids by administration of solid pharmaceutical dosage formulation comprising a hiv protease inhibitor in fasted state
CL2007000806A1 (en) heteropentaciclos derivatives substituted compounds; Preparation process; intermediate compounds; pharmaceutical composition; and use in the treatment of cancer.
BRPI0520082A2 (en) dosage forms of risedronate
UY30444A1 (en) Pyrimidine derivatives, processes for their preparacinn, farmaccuticos compositions and uses thereof.
PA8780201A1 (en) Pirasol derivatives substituted heteroaryl useful for treating hyperproliferative disorders and diseases associated with angiogenesis
ECSP10010015A (en) Proteasome inhibitors
CL2014001450A1 (en) Solid dosage form comprising a controlled release opioid analgesic dispersed in a matrix material; Preparation method; use in the treatment of pain.
PA8660301A1 (en) Pyrazolo substituted pyridines, compositions containing them, process manufacture and use